Zacks Research Analysts Reduce Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW) – Zacks Research dropped their Q1 2025 EPS estimates for shares of Edwards Lifesciences in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $0.58 per share for the quarter, down from their previous forecast of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.61 EPS, FY2025 earnings at $2.42 EPS, Q1 2026 earnings at $0.66 EPS, Q2 2026 earnings at $0.69 EPS and FY2026 earnings at $2.78 EPS.

Several other equities analysts have also commented on the stock. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. UBS Group dropped their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Truist Financial decreased their price objective on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Oppenheimer reiterated an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Finally, Piper Sandler decreased their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Stock Up 0.2 %

NYSE EW opened at $70.49 on Friday. The stock has a 50 day moving average price of $67.70 and a 200-day moving average price of $75.73. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company has a market capitalization of $41.58 billion, a P/E ratio of 10.17, a P/E/G ratio of 3.95 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the company earned $0.59 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $2,657,000 in the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds have recently added to or reduced their stakes in EW. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences during the first quarter valued at $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $29,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth about $32,000. Finally, Avior Wealth Management LLC grew its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.